Biodegradable microfuses to enable the safe and compliant long-term interval dosing of 5HT2A agonists
可生物降解的微熔丝可实现 5HT2A 激动剂安全、合规的长期间隔给药
基本信息
- 批准号:10372879
- 负责人:
- 金额:$ 18.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-24 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcetatesAcidsAddressAffectAgonistAutopsyCelluloseCenters of Research ExcellenceCharacteristicsClinicalClinical ResearchClinical TrialsCreativenessDevicesDoseDrug Delivery SystemsDrug KineticsEffectivenessElectronsEnsureExposure toFilmGoalsGrantGrowthHallucinogensHistopathologyImmune responseImmunocompetentImplantIn VitroIngestionInvestigationKetamineKineticsLettersLiquid substanceLysergic Acid DiethylamideMajor Depressive DisorderMedicalMedical Care CostsMental DepressionMental disordersMicrofluidicsMicroscopyMississippiModalityMoodsMusNatural ProductsNeedlesNeurosciencesOccupationalOrganPatientsPharmaceutical PreparationsPharmacotherapyPhysiologic pulsePluronicsPolymersPopulationPositioning AttributePsychiatryPsychotherapyRegimenReportingResearchResearch PersonnelResistanceScanningScheduleSeriesSerumSiteStructureSuicide attemptSurfaceSymptomsSystemTechnologyTherapeuticTimeToxicologyTranslatingTreatment ProtocolsTrocarsUniversitiesWalkersWorkalternative treatmentbasebiomaterial compatibilitycaprolactoneclinical investigationclinical translationcommercializationcompliance behaviorcostcravingdepressive symptomsdisabling symptomeffective therapyexperiencefollow-uphigh rewardhigh riskimplantationimprovedin vitro Assayin vivoinnovationmicrodevicephthalatespolycaprolactonepreclinical studypreventprototypepsychologicreduce symptomssocialsubcutaneoussuicide ratetechnology developmenttreatment-resistant depression
项目摘要
Abstract
There is an urgent unmet medical need to develop therapeutic options for the ~50% of depression patients
suffering from treatment-resistant depression, a form of depression resistant to treatment by existing psycho-
and pharmaco-therapies. Classical psychedelics, such as the 5HT2A agonists lysergic acid diethylamide (LSD)
and psilocybin, have re-emerged as a treatment option for patients with depression that is treatment-resistant.
Recent clinical trials highlight the potential effectiveness of 5HT2A agonists to improve mood and
psychotherapeutic growth in treatment-resistant depression patients, even in those who have failed a median of
4 previous medications in their lifetime. Accordingly, the FDA recently granted “Breakthrough Therapy”
designation to psilocybin for treatment-resistant depression. The improvements associated with 5HT2A agonist
pharmacotherapy last for weeks to months, a marked increase relative to ketamine, but administration requires
a 6-8-hr psychological support session, an approach which is unlikely to scale. Moreover, many patients find
their symptoms recur and need repeat administration. ‘Microdosing’ – ingesting subperceptual doses of
psychedelics every 3-7 days to improve mood and/or creativity – represents an alternative, potentially long-term
treatment option. Microdosing has become prominent in the lay public, with recent scientific studies corroborating
anecdotal claims that it improves mood, energy levels, social connectedness, and decreases craving for
addictive substances. However, there are a gamut of practical barriers that stymie further investigation of 5HT2A
agonists microdosing in the clinical setting, including: low compliance with the complicated dosing regimen, high
risk of diversion of controlled substances, and difficulty and cost administering the long-term treatment regimens
in controlled settings. Here, we propose to overcome the above limitations by developing a bioresorbable
microdosing implant (MDI) composed of “microfluidic fuses”, or µfuses, that enables long-term, intermittent
delivery of sub-perceptual microdoses of 5HT2A agonists. The µfuses are composed of a 70:30 mixture of
Cellulose Acetate Phthalate (CAP) and Pluronic® F-127 (P) polymers which form a surface-eroding film. CAPP
µfuses will be embedded in a slowly biodegrading polycaprolactone (PCL) body and sit atop 5HT2A agonist-
containing drug reservoirs in series. As the CAPP µfuse erodes, the reservoirs will be exposed to the surrounding
fluid and release pulses of 5HT2A agonist, where the timing between pulses is controlled by the distance between
reservoirs beneath the µfuse. We will develop the CAPP µfuse technology in two aims. 1) Microfabricate and
validate the function of µfuse devices in vitro. 2) Characterize the in vivo pharmacokinetics and biocompatibility
of prototype µfuse devices in immune-competent, healthy mice. Successful development of this technology will
enable unprecedented studies into the merits of 5HT2A microdosing as a therapeutic strategy to overcome
treatment-resistant depression.
抽象的
为约 50% 的抑郁症患者开发治疗方案是一项迫切且未得到满足的医疗需求
患有难治性抑郁症,这是一种对现有心理治疗有抵抗力的抑郁症。
和药物治疗。经典迷幻药,例如 5HT2A 激动剂麦角酸二乙酰胺 (LSD)
和裸盖菇素,已重新成为治疗耐药的抑郁症患者的治疗选择。
最近的临床试验强调了 5HT2A 激动剂在改善情绪和改善情绪方面的潜在功效。
难治性抑郁症患者的心理治疗增长,即使是那些中位数失败的患者
一生中曾服用过 4 种药物。因此,FDA 最近授予“突破性疗法”
指定裸盖菇素用于治疗难治性抑郁症。与 5HT2A 激动剂相关的改善
药物治疗持续数周至数月,相对于氯胺酮显着增加,但给药需要
6-8 小时的心理支持课程,这种方法不太可能扩大规模。而且,很多患者发现
他们的症状反复出现,需要重复给药。 “微剂量”——摄入亚知觉剂量的
每 3-7 天使用迷幻药来改善情绪和/或创造力——代表一种替代方案,可能是长期的
治疗选择。最近的科学研究证实,微剂量在普通公众中已经变得很突出
传闻称它可以改善情绪、精力水平、社交联系,并减少对食物的渴望
成瘾物质。然而,存在一系列实际障碍阻碍了 5HT2A 的进一步研究
临床环境中的激动剂微剂量,包括:对复杂给药方案的依从性低、高
受控物质转移的风险以及实施长期治疗方案的难度和成本
在受控设置中。在这里,我们建议通过开发一种生物可吸收的材料来克服上述限制
微剂量植入物 (MDI) 由“微流体保险丝”或 µfuse 组成,可实现长期、间歇性
5HT2A 激动剂的亚感知微剂量的递送。 µfuses 由 70:30 的混合物组成
邻苯二甲酸醋酸纤维素 (CAP) 和 Pluronic® F-127 (P) 聚合物可形成表面侵蚀膜。计算机辅助应用程序
µfuse 将嵌入缓慢生物降解的聚己内酯 (PCL) 体内,并位于 5HT2A 激动剂的顶部 -
含有串联的药物储存器。当 CAPP µfuse 腐蚀时,储层将暴露在周围环境中
5HT2A激动剂的液体和释放脉冲,其中脉冲之间的时间由之间的距离控制
µfuse 下方的水库。我们将出于两个目标开发 CAPP µfuse 技术。 1) 微加工和
体外验证 µfuse 器件的功能。 2) 表征体内药代动力学和生物相容性
在具有免疫能力的健康小鼠中进行原型微熔丝装置的研究。该技术的成功开发将
能够对 5HT2A 微剂量作为治疗策略的优点进行前所未有的研究,以克服
难治性抑郁症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Glenn Madison Walker其他文献
Glenn Madison Walker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Glenn Madison Walker', 18)}}的其他基金
Biodegradable microfuses to enable the safe and compliant long-term interval dosing of 5HT2A agonists
可生物降解的微熔丝可实现 5HT2A 激动剂安全、合规的长期间隔给药
- 批准号:
10494241 - 财政年份:2021
- 资助金额:
$ 18.25万 - 项目类别:
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
CAREER: Highly Rapid and Sensitive Nanomechanoelectrical Detection of Nucleic Acids
职业:高度快速、灵敏的核酸纳米机电检测
- 批准号:
2338857 - 财政年份:2024
- 资助金额:
$ 18.25万 - 项目类别:
Continuing Grant
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 18.25万 - 项目类别:
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 18.25万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 18.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 18.25万 - 项目类别:
Continuing Grant
Integrated understanding and manipulation of hypoxic cellular functions by artificial nucleic acids with hypoxia-accumulating properties
具有缺氧累积特性的人工核酸对缺氧细胞功能的综合理解和操纵
- 批准号:
23H02086 - 财政年份:2023
- 资助金额:
$ 18.25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 18.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 18.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 18.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synthetic analogues based on metabolites of omega-3 fatty acids protect mitochondria in aging hearts
基于 omega-3 脂肪酸代谢物的合成类似物可保护衰老心脏中的线粒体
- 批准号:
477891 - 财政年份:2023
- 资助金额:
$ 18.25万 - 项目类别:
Operating Grants